好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Gender Differences in Distribution of Lewy Body Pathology in Individuals with Parkinson's Disease
Movement Disorders
S17 - Parkinson's Disease Biomarkers and Pathophysiology (2:12 PM-2:24 PM)
007

To determine if there are gender differences in distribution of Lewy Body pathology among individuals with Parkinson’s disease (PD).

There is increasing evidence that gender is an important factor in cognitive functioning in PD. One study found that women performed better on verbal learning and memory, whereas men had better visuospatial functioning (1). We hypothesized that gender differences may exist in the brain distribution of Lewy bodies (LB), potentially explaining these cognitive differences.

We evaluated individuals with a pathological diagnosis of PD, defined by the presence of LBs, from the autopsy program of the Johns Hopkins Morris K. Udall Parkinson’s Disease Research Center, which has been ongoing since 1999. First, we conducted a logistic regression to determine if LB distribution, classified as: limited to the brainstem only, extending to the limbic region, or extending into the neocortex, differed between males and females with PD when controlling for age, education, illness duration and cognitive status (normal, MCI, dementia) (n=188). Then, we conducted a Mann-Whitney analysis to determine if there was a gender difference in LB severity score (0-4) in the following brain regions: Frontal Lobe, Anterior Cingulate, Temporal Lobe, Amygdala, Locus Coeruleus (LC), Transentorhinal, Nucleus Basalis, Cranial Nerves IX and X, and Substantia Nigra for individuals with PD and a diagnosis of possible, probable or definite dementia (n=133).

We saw no association between gender and LB distribution when classified as brainstem, limbic or neocortex. However, women have a higher LB severity score in the Frontal lobe, Amygdala, and LC (n=102,p=0.04; n=80, p=0.04; n=76, p=0.02, respectively).

In this analysis, women were found to have higher LB severity scores in three major brain regions that affect cognition. Further investigation is required to determine whether the differences in scores for these brain regions correspond to specific gender differences in the cognitive characteristics of PD.

Authors/Disclosures
Katherine G. Iannuzzelli (Johns Hopkins)
PRESENTER
No disclosure on file
No disclosure on file
Jumana T. Alshaikh, MD (University of Utah) Dr. Alshaikh has nothing to disclose.
Jee Bang, MD (Johns Hopkins University) Dr. Bang has received personal compensation in the range of $0-$499 for serving as a Consultant for GLG. Dr. Bang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Adept Field Solutions.
Ankur Butala, MD (Johns Hopkins) The institution of Dr. Butala has received research support from National Institutes of Mental Health.
No disclosure on file
Emile S. Moukheiber, MD (Johns Hopkins Hospital) Dr. Moukheiber has nothing to disclose.
Maitreyi Murthy, MD (Peacehealth Southwest Medical Group) Dr. Murthy has nothing to disclose.
Alexander Pantelyat, MD, FAAN (Johns Hopkins University School of Medicine) Dr. Pantelyat has received personal compensation for serving as an employee of MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Kelly & Ignoffo Law Group. The institution of Dr. Pantelyat has received research support from NIH/NIA.
No disclosure on file
No disclosure on file
Gerson Suarez-Cedeno, MD (University of New Mexico) Dr. Suarez-Cedeno has nothing to disclose.
Juan C. Troncoso, MD No disclosure on file
Kelly A. Mills, MD (Johns Hopkins University) Dr. Mills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tilosia. The institution of Dr. Mills has received research support from NINDS. The institution of Dr. Mills has received research support from MJFF. The institution of Dr. Mills has received research support from GKC.
Ted M. Dawson, MD, PhD, FAAN (Institute for Cell Engineering, Johns Hopkins University School of Medicine) Dr. Dawson has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Valted Seq Inc. An immediate family member of Dr. Dawson has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Valted Seq Inc. An immediate family member of Dr. Dawson has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for eNeuro. Dr. Dawson has stock in Valted Seq. Dr. Dawson has stock in American Gene Technologies International Inc. Dr. Dawson has stock in Inhibikase Therapeutics, Inc. Dr. Dawson has stock in D&D Pharmatech. Dr. Dawson has stock in Abbvie. An immediate family member of Dr. Dawson has stock in Valted Seq Inc. An immediate family member of Dr. Dawson has stock in Inhibikase Therapeutics. An immediate family member of Dr. Dawson has stock in D&D Pharmatech. The institution of Dr. Dawson has received research support from Sun Pharmaceutical Industries Ltd. The institution of Dr. Dawson has received research support from Aevum. Dr. Dawson has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dawson has received intellectual property interests from a discovery or technology relating to health care. Dr. Dawson has received personal compensation in the range of $100,000-$499,999 for serving as a Advisor with Mitokinin.
Liana Rosenthal, MD (Johns Hopkins School of Medicine) Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven Pharmaceuticals. Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Reata Pharmaceuticals. Dr. Rosenthal has received research support from NIH. Dr. Rosenthal has received research support from Gordon and Marilyn Macklin Foundation. Dr. Rosenthal has received research support from The Daniel B. and Florence E. Green Foundation. Dr. Rosenthal has received research support from National Ataxia Foundation. Dr. Rosenthal has received research support from Michael J. Fox Foundation. Dr. Rosenthal has received research support from Pfizer. Dr. Rosenthal has received research support from Biohaven Pharmaceuticals. Dr. Rosenthal has a non-compensated relationship as a Medical Director, ex-officio Member of the Board with National Ataxia Foundation that is relevant to AAN interests or activities.